Secondly, we investigated if baseline levels of glutamate/Cr and GABA/Cr differed in NR patients after 1.5 and 6 months' treatment using ANOVA. In the left thalamus, NR patients after both 1.5 and 6 months had significantly higher baseline glutamate/Cr compared with HC (P1.5months=0.03 and P6months<0.05), whereas R and HC did not differ. In the ACC, NR after 1.5 months showed a trend for lower GABA/Cr at baseline (p=0.06), and in NR after 6 months baseline GABA/Cr was significantly lower compared with HC (p=0.03), whereas R and HC did not differ. In the ACC, there was no baseline difference in glutamate/Cr of NR patients after 1.5 and 6 months compared with HC. Discussion: The findings indicate increased glutamatergic turnover in the left thalamus and decreased GABAergic neurotransmission in the ACC in the pathophysiology of schizophrenia. Treatment normalises glutamate levels in the left thalamus, but does not affect GABA and glutamate levels in the ACC. Importantly, NR patients are characterized by more pronounced glutamatergic and GABAergic disturbances in the antipsychotic-naïve state. Compounds that modify glutamatergic and GABAergic neurotransmission might have therapeutic potential in this subgroup. Background: Offspring of patients with schizophrenia and bipolar disorder are at increased risk to develop psychopathology. It has been suggested that the development of these disorders may be a result of early neurodevelopmental abnormalities. The intracranial volume (ICV) is a direct marker for neurodevelopment in the early years, as ICV reaches 90% of its full size around the age of five. Interestingly, a smaller ICV is more consistently found in SZ patients, compared to controls, than in bipolar disorder patients. The offspring of these two patients group may provide important information on the putative neurodevelopmental trajectory underlying the development of these disorders. We compared ICV between offspring of at least one parent with SZ (SZo) or BD (BDo) and control offspring (Co) in relation to IQ and the presence of psychopathology. Methods: A large sample of children and adolescents (8-18 years old; 54 SZo, 90 BDo, and 46 Co) was included. T1-weighted (3-Tesla) MRI brain scans were available for 146 participants. Group differences in ICV, global and local brain measures, psychopathology (K-SADS-PL, CBCL/6-18), IQ (WISC-III/WAIS-III), and their interactions were analyzed. FreeSurfer-5.3.0 was used for subcortical and cortical volume, cortical thickness, and cortical surface area estimations. Groups were compared using linear mixed effects modeling, corrected for family dependencies. FDR-correction was applied. Results: Our main finding was that ICV was significantly smaller in SZo, compared to BDo and Co. IQ was significantly lower in both SZo and BDo, relative to Co, but could not explain the smaller ICV in SZo. ICV was also not explained by psychopathology, even though there was no significant difference in 'any psychopathology' between SZo and BDo. There was however some illness specificity as BDo had a higher prevalence of 'any mood disorder' as compared with Co, and SZo had a higher prevalence of major depressive disorder and autism spectrum disorders as compared with BDo and Co. After correcting for ICV, the cortex was significantly thinner in SZo compared to BDo and Co, and BDo had larger lateral ventricles than
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Background: Offspring of patients with schizophrenia and bipolar disorder are at increased risk to develop psychopathology. It has been suggested that the development of these disorders may be a result of early neurodevelopmental abnormalities. The intracranial volume (ICV) is a direct marker for neurodevelopment in the early years, as ICV reaches 90% of its full size around the age of five. Interestingly, a smaller ICV is more consistently found in SZ patients, compared to controls, than in bipolar disorder patients. The offspring of these two patients group may provide important information on the putative neurodevelopmental trajectory underlying the development of these disorders. We compared ICV between offspring of at least one parent with SZ (SZo) or BD (BDo) and control offspring (Co) in relation to IQ and the presence of psychopathology. Methods: A large sample of children and adolescents (8-18 years old; 54 SZo, 90 BDo, and 46 Co) was included. T1-weighted (3-Tesla) MRI brain scans were available for 146 participants. Group differences in ICV, global and local brain measures, psychopathology (K-SADS-PL, CBCL/6-18), IQ (WISC-III/WAIS-III), and their interactions were analyzed. FreeSurfer-5.3.0 was used for subcortical and cortical volume, cortical thickness, and cortical surface area estimations. Groups were compared using linear mixed effects modeling, corrected for family dependencies. FDR-correction was applied. Results: Our main finding was that ICV was significantly smaller in SZo, compared to BDo and Co. IQ was significantly lower in both SZo and BDo, relative to Co, but could not explain the smaller ICV in SZo. ICV was also not explained by psychopathology, even though there was no significant difference in 'any psychopathology' between SZo and BDo. There was however some illness specificity as BDo had a higher prevalence of 'any mood disorder' as compared with Co, and SZo had a higher prevalence of major depressive disorder and autism spectrum disorders as compared with BDo and Co. After correcting for ICV, the cortex was significantly thinner in SZo compared to BDo and Co, and BDo had larger lateral ventricles than Co. Without correction for ICV, volumes of the total brain and gray matter were significantly smaller in SZo than in BDo and Co. Cortical white matter volume was significantly smaller in SZo as compared with Co. Discussion: Irrespective of a lower IQ and increased presence of psychopathology in both high-risk offspring groups, abnormal early brain development, expressed as smaller ICV, differentiates offspring of patients with schizophrenia from offspring of patients with bipolar disorder and offspring of healthy parents. This suggest that the risk for schizophrenia is, in contrast to that in bipolar disorder, characterized by stunted brain development. Background: People with schizophrenia and related psychotic disorders show abnormalities in several organ systems in addition to the central nervous system (CNS). It is not yet known how the magnitude of disturbance in non-CNS systems compares with the magnitude of CNS disturbance in FEP. Here, we statistically compare effect sizes (ES) for non-CNS and CNS dysfunction in FEP, and consider whether schizophrenia is a multi-system disorder. Methods: Pubmed was systematically searched from 1990 to May 2017 for meta-analyses examining non-CNS dysfunction in FEP, focusing on immune, cardiometabolic, and hypothalamic-pituitary-adrenal (HPA) systems. A parallel search was performed for meta-analyses examining representative CNS dysfunction in FEP, specifically neurophysiological, neurochemical and brain structural alterations. To statistically compare the magnitude of effect sizes (ES) between different CNS and non-CNS systems in FEP, data were extracted from case-control studies making up these meta-analyses, and meta-analyses repeated. For non-CNS parameters, random-effects meta-analyses were performed examining immune (cytokines, CRP, and lymphocytes), cardiometabolic (glucose/insulin and lipids), and HPA parameters (cortisol and prolactin). For CNS parameters, meta-analyses were performed examining brain structural, neurophysiological (Auditory P300 amplitude and latency, duration deviant mismatch negativity), and neurochemical parameters (N-acetylaspartic acid levels). Standardized mean differences between patient and control cohort parameters were used as the ES (Hedges adjusted g). As well as individual metaanalyses being run for each parameter as described, 6 separate sub-group meta-analyses were performed examining data for overall immune, cardiometabolic, HPA, brain structural, neurophysiological, and neurochemical systems. Sub-group summary effect size magnitudes were calculated by running a combined analysis of all studies assigned to a sub-group (e.g. to calculate the summary effect size magnitude for immune alterations, a single analysis was performed that combined IL-1b, sIL-2R, IL-6, TNFa, TGFb, CRP, and lymphocyte count data sets). Summary effect sizes for these 6 individual systems were statistically compared in a fixed effects model using a Wald-type test. This was also used to compare overall summary CNS and non-CNS effect sizes. Antipsychotic naïve sensitivity analyses were performed. Results: Data were extracted for 165 studies comprising a total sample size of 13,440. The summary effect size for immune alterations (g=1.19; CI:0.82-1.56) was significantly greater than brain structural (g=0.40;P<.001) and neurochemical alterations (g=0.43;P<.001), and no different from neurophysiological alterations (g=0.80; P=0.05). The summary effect size for HPA alterations (g=0.68; CI:0.32-1.04) was not significantly different from brain structural (P=.14), neurophysiological (P=.54), and neurochemical (P=.22) alterations. The summary effect size for cardiometabolic alterations (g=0.23; CI:0.15-0.31) was significantly lower than neurochemical (P=.04), neurophysiological (P<.001) and brain structural alterations (P=.001). The overall summary effect sizes for non-CNS (g=0.58; CI:0.44-0.72) and CNS (g=0.50; CI:0.44-0.56) alterations were not significantly different (P=.28). Discussion: These data indicate that there are robust alterations in non-CNS systems in psychosis, and that these are broadly similar in magnitude to a range of CNS alterations, indicating that psychosis involves multiple organ systems to a comparable degree from onset. We consider three models that could account for these findings and discuss implications for future research and treatment. Background: Short telomere length is a biomarker of cell oxidation and aging. Patients with first-episode psychosis (FEP) have been reported to have shorter telomeres than healthy controls (HC), suggesting that there is a premature and accelerated cellular aging in FEP. However, there are not data on longitudinal changes of telomere length in people with FEP relative to HC. We present preliminary results on 1-year longitudinal changes in peripheral blood mononuclear cells (PBMCs) telomere length and the proportion of PBMCs with short telomeres in young people with FEP and HC. Methods: 16 young patients with FEP (43.8% female, mean age 17.9 years) and 21 young HC (61.9% female, mean age 16.6 years) were enrolled in the study. PBMCs telomere length and the proportion of PBMCs with short telomeres (i.e. <3kb) were determined using high-throughput quantitative fluorescence in situ hybridization (HT Q-FISH) at baseline (16 patients with FEP and 21 HC) and 12-month follow-up (4 patients with FEP and 4 HC). Results: At baseline, we did not find significant differences in telomere length nor in proportion of PBMCs with short telomeres between FEP patients and HC. During the one-year follow-up, we found a significantly greater loss of telomere length (p=0.019; explained variance=69.7%) and a non-significantly trend for greater increase in the proportion of PBMCs with short telomeres (p=0.097; explained variance=45.5%) in patients with FEP than in HC. Discussion: Telomere length changes during the first years of the illness can represent an early marker of accelerated cellular aging in patients with firstepisode psychosis.
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